Advertisement

Rheumatology International

, Volume 33, Issue 2, pp 273–276 | Cite as

Leflunomide: friend or foe for systemic lupus erythematosus?

  • Guo-Cui Wu
  • Xiao-Di Xu
  • Qiong Huang
  • Hua WuEmail author
Review Article

Abstract

Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.

Keywords

Leflunomide Systemic lupus erythematosus Therapy 

Notes

Acknowledgments

This work is supported by the Scientific Research Funds of Anhui Medical University (2011xkj088) and the National Natural Science Foundation of China (81002192).

Conflict of interest

No competing financial interests exist.

References

  1. 1.
    Smolen JS, Graninger WB, Emery P (2000) Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford) 39:689–692CrossRefGoogle Scholar
  2. 2.
    Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550PubMedCrossRefGoogle Scholar
  3. 3.
    Smolen JS, Kalden JR, Scott DL et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266PubMedCrossRefGoogle Scholar
  4. 4.
    Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655–665PubMedCrossRefGoogle Scholar
  5. 5.
    Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59:841–849PubMedCrossRefGoogle Scholar
  6. 6.
    Popovic S, Bartlett RR (1987) The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 21:284–286PubMedCrossRefGoogle Scholar
  7. 7.
    Bartlett RR, Popovic S, Raiss RX (1988) Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 75:290–299PubMedCrossRefGoogle Scholar
  8. 8.
    Petera P, Manger B, Rosenburg R et al (2000) A pilot study of leflunomide in systemic lupus erythematosus (SLE). Arthritis Rheum 43:S241Google Scholar
  9. 9.
    Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10:480–483PubMedCrossRefGoogle Scholar
  10. 10.
    Petri M (2001) High dose arava in lupus (HAIL). Arthritis Rheum 44:S280Google Scholar
  11. 11.
    Kessel A, Toubi E (2002) Leflunomide in systemic lupus erythematosus. Harefuah 141:355–357PubMedGoogle Scholar
  12. 12.
    Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13:601–604PubMedCrossRefGoogle Scholar
  13. 13.
    Cui TG, Hou FF, Ni ZH et al (2005) Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi 44:672–676 [In Chinese]PubMedGoogle Scholar
  14. 14.
    Tam LS, Li EK, Wong CK et al (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65:417–418PubMedCrossRefGoogle Scholar
  15. 15.
    Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17:638–644PubMedCrossRefGoogle Scholar
  16. 16.
    Holm EA, Balslev E, Jemec GB (2001) Vasculitis occurring during leflunomide therapy. Dermatology 203:258–259PubMedCrossRefGoogle Scholar
  17. 17.
    Carulli MT, Davies UM (2002) Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology 41:952–953PubMedCrossRefGoogle Scholar
  18. 18.
    Soliotis F, Glover M, Jawad AS (2002) Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis 61:850–851PubMedCrossRefGoogle Scholar
  19. 19.
    Chan AT, Bradlow A, McNally J (2003) Leflunomide induced vasculitisea dose-response relationship. Rheumatology 42:492–493PubMedCrossRefGoogle Scholar
  20. 20.
    Fischer TW, Bauer HI, Graefe T et al (2003) Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 207:386–389PubMedCrossRefGoogle Scholar
  21. 21.
    van Roon EN, Jansen TL et al (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 27:345–352PubMedCrossRefGoogle Scholar
  22. 22.
    Chan J, Sanders DC, Du L et al (2004) Leflunomide associated pancytopenia with or without methotrexate. Ann Pharmacother 38:1206–1211PubMedCrossRefGoogle Scholar
  23. 23.
    Bharadwaj A, Haroon N (2004) Peripheral neuropathy in patients on leflunomide. Rheumatology 43:934PubMedCrossRefGoogle Scholar
  24. 24.
    Bonnel RA, Graham DJ (2004) Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 75:580–585PubMedCrossRefGoogle Scholar
  25. 25.
    Kamata Y, Nara H, Kamimura T et al (2004) Rheumatoid arthritis complicated with acute intersitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 43:1201–1204PubMedCrossRefGoogle Scholar
  26. 26.
    Kerr OA, Murray CS, Tidman MJ (2004) Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 29:319–320PubMedCrossRefGoogle Scholar
  27. 27.
    Goeb V, Berhelot JM, Joly P et al (2005) Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology 44:823–824PubMedCrossRefGoogle Scholar
  28. 28.
    Gensburger D, Kawashima M, Marotte H et al (2005) Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 64:153–155PubMedCrossRefGoogle Scholar
  29. 29.
    Takeishi M, Akiyama Y, Akiba H et al (2005) Leflunomide induced acute interstitial pneumonia. J Rheumatol 32:1160–1163PubMedGoogle Scholar
  30. 30.
    Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208PubMedCrossRefGoogle Scholar
  31. 31.
    González-Alvaro I, Ortiz AM, Domínguez-Jiménez C et al (2009) Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 68:1644–1650PubMedCrossRefGoogle Scholar
  32. 32.
    Manna SK, Mukhopadhyay A, Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 165:5962–5969PubMedGoogle Scholar
  33. 33.
    Manna SK, Aggarwal BB (1999) Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 162:2095–2102PubMedGoogle Scholar
  34. 34.
    He C, Lu X, Yan Z et al (2012) Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int 32:633–638PubMedCrossRefGoogle Scholar
  35. 35.
    Bes C, Soy M (2011) Pseudo-pseudo Meigs syndrome developed under the leflunomide therapy. Rheumatol Int 31:521–523PubMedCrossRefGoogle Scholar
  36. 36.
    Suess A, Sticherling M (2008) Leflunomide in subacute cutaneous lupus erythematosus-two sides of a coin. Int J Dermatol 47:83–86PubMedCrossRefGoogle Scholar
  37. 37.
    Chan SK, Hazleman BL, Burrows NP (2004) Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 29:724–725Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of PharmacyBinhu Hospital, The First People’s Hospital of Hefei CityHefeiChina

Personalised recommendations